Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
|Slideshows|November 21, 2019
6 key symptoms of hyperactivity to consider for an ADHD diagnosis
When considering a diagnosis of attention-deficit/hyperactivity disorder (ADHD), it's important for the clinician to keep an eye out for symptoms of hyperactivity. Here are 6 key symptoms to aid in diagnosis.
Advertisement
Advertisement
Related to this article
FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Can you guess the diagnosis?
DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
ScolimiR-3D, a 6-microRNA blood test to predict severe curve progression in AIS, received FDA Breakthrough Device designation.
Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
What the Camzyos approval means for patients with obstructive HCM
2
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
3
FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy
4
First-in-human trial tests microneedle stamp approach for peanut allergy
5